Skip to main content

Advertisement

SpringerLink
Log in

Die richtige Formulierung zum Erhalt der Qualität therapeutischer Proteine

  • Biotechnologie
  • Biopharmazeutika
  • Published:
BIOspektrum Aims and scope

Zusammenfassung

Die biotechnologische Herstellung therapeutischer Proteine ist ein aufwendiger und streng regulierter Prozess. Die richtige Formulierung und deren Entwicklung ist eine grundlegende Voraussetzung zur Gewährleistung der Qualität und des Erfolgs eines biopharmazeutischen Produktes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Shukla AA, Hubbard B, Tressel T et al. (2007) Downstream processing of monoclonal antibodies — application of platform approaches. J Chromatogr B 848:28–39

    Article  CAS  Google Scholar 

  2. Bergeman K, Eckermann C, Garidel P et al. (2007) Production and Downstream Processing. In: Dübel S (Hrsg) Handbook of Therapeutic Antibodies. Wiley-VCH, Weinheim

    Google Scholar 

  3. McNally EJ, Hastedt JE (2007) Protein Formulation and Delivery. Informa Healthcare Inc., New York

    Google Scholar 

  4. Mahler HC, Borchard G, Luessen H (2010) Characterization of Proteins and Related Analytical Techniques. In: Protein Pharmaceuticals. Editio Cantor Verlag, Aulendorf, 44–90

    Google Scholar 

  5. Shechter Y, Burstein Y, Patchornik A (1975) Selective oxidation of methionine residues in proteins. Biochemistry 14:4497–4503

    Article  PubMed  CAS  Google Scholar 

  6. Qi P, Volkin DB, Zhao H et al. (2008) Characterization of the photodegradation of a human IgG1 monoclonal antibody. J Pharm Sci 98:3117–3129

    Article  Google Scholar 

  7. Yu J (2000) Intentionally degrading protein pharmaceuticals to validate stability indicating analytical methods. Biopharm:46–50

  8. Grillo AO, Kane M, Penn N et al. (2010) Characterizing the formulation design space. Biopharm Int:30–39

  9. He F, Hogan S, Latypov RF et al. (2010) High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 9:1707–1720

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rentschler Biotechnologie GMBH, Laupheim, Germany

    Alexander Faude & Frank Kohne

  2. Rentschler Biotechnologie GmbH, Erwin-Rentschler-Straße 21, D-88471, Laupheim, Germany

    Alexander Faude

Authors
  1. Alexander Faude
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Kohne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Faude.

Additional information

Alexander Faude (links) und Frank Kohne

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faude, A., Kohne, F. Die richtige Formulierung zum Erhalt der Qualität therapeutischer Proteine. Biospektrum 17, 233–235 (2011). https://doi.org/10.1007/s12268-011-0035-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12268-011-0035-1

Search

Navigation